News - ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PIPELINE Press Uncategorized

Anavex to Present at the 2016 Rett Syndrome Symposium

Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms

ANAVEX 2‐73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology.

2016 Rett Syndrome Symposium

Sigma-1 Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX 2-73 in a Fragile X Model.

AAT Presentation

Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome

Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms

Anavex Reports Fiscal Second Quarter 2016 Financial Results